
äžè¬çãªè¡å§è¬ãããæ²»çãå€§å¹ ã«åŒ·åââPARPé»å®³å€ã®å¹æãå¢åŒ·
PARPé»å®³å€ïŒãªã©ããªããªã©ïŒã¯éå»10幎éã§æãéèŠãªããæ²»çè¬ã®äžã€ã§ããããæ¬è³ªçãªéçãããïŒDNAä¿®åŸ©ã«æ¢ã«æ¬ é¥ãããè «çââæãæåãªã®ã¯BRCAå€ç°ââã§ãã广ãçºæ®ããªãããçžåçµæã competentããªçã®å€§éšåââä¹³çã®çŽ90ïŒ ãåµå·£çã®çŽ80ïŒ ââã§ã¯ãPARPé»å®³å€ã¯ã»ãšãã©æ©æµããããããªãã ããŒããã¹çã»ã³ã¿ãŒã®ç ç©¶è ãã«ãã£ãŠJournal for ImmunoTherapy of Cancerã«çºè¡šãããç ç©¶ã¯ããã®éçãåé¿ããæœåšçãªæ¹æ³ãæããã«ããïŒå®äŸ¡ã§åºã䜿çšãããŠããè¡å§è¬ãã«ããµã«ã¿ã³ããèªç¶å ç«ç³»ã掻æ§åããããšã«ãããBRCAé°æ§è «çã§ããªã©ããªãã®å¹æãåçã«é«ããã®ã§ããã ãåèšåºã¢ãã«ã«ãããŠããã«ããµã«ã¿ã³ãšãªã©ããªãã®äœµçšã¯è «ç墿®ã匷åã«æå¶ããããã©ã¡ããäžæ¹ã ãã§ã¯å¹æã¯ç¡èŠã§ããçšåºŠã§ãããšãããŒããã¹å€§åŠã¬ã€ãŒã«å»åŠå€§åŠé¢ã®å»åŠææã§äžåžèè ã®Tyler J. Curielæ°ã¯è¿°ã¹ããããããããã®ã¡ã«ããºã ã¯åŸæ¥ã®PARPé»å®³å€ã¢ãããŒããšã¯å®å šã«ç°ãªããŸããã å€è§çãªã¡ã«ããºã ãã«ããµã«ã¿ã³ã¯ã¢ã³ãžãªãã³ã·ã³IIåå®¹äœæ®æè¬ïŒARBïŒç³»ã®éå§è¬ã«å±ããããç ç©¶ã«ããã°ããã®ç墿广ã¯ã¯ã©ã¹å šäœã®ç¹æ§ã§ã¯ãªãã詊éšããã6çš®é¡ã®ARBã®ãã¡ããã«ããµã«ã¿ã³ã®ã¿ãè «çPD-L1ãæžå°ãããçŽ°èæ ªã«ãããŠãªã©ããªããšçžä¹å¹æã瀺ããã ãã®ã¡ã«ããºã ã¯è€æ°ã®å±€ããæãã现èã¬ãã«ã§ã¯ããã«ããµã«ã¿ã³ãšãªã©ããªãã®äœµçšã¯DNAæå·ïŒäºæ¬éåæã®ããŒã«ãŒã§ããγH2AXã§æž¬å®ïŒãå€§å¹ ã«å¢å ãããããæ£åžžçŽ°èã«ã¯åæ§ã®æå·ãèªå°ããªãããã®æå·ã¯ãåŸæ¥ã®PARPé»å®³å€å¢ææŠç¥ã®ããã«è «çã®DNA修埩çµè·¯ãæãªãããšã«ãã£ãŠçããã®ã§ã¯ãªãããŸã£ããç°ãªãçµè·¯ã«ãããã®ã§ããïŒçްèè³ªã«æŒåºããDNAæçãcGAS-STINGçµè·¯ââ现è質DNAã®äžå¿çã»ã³ãµãŒââãæŽ»æ§åããããããIåã€ã³ã¿ãŒãã§ãã³ïŒå ç«å¿çã orchestrate ããã·ã°ãã«äŒéååïŒã®ç£çãåŒãèµ·ããã ããŠã¹ã¢ãã«ã«ãããŠããã®ã€ã³ã¿ãŒãã§ãã³å¿çã¯äœµçšçæ³ã®æè «ç广ã«å¿ é ã§ãã£ããç ç©¶è ããæäœã§Iåã€ã³ã¿ãŒãã§ãã³ã·ã°ãã«äŒéã鮿ããããã€ã³ã¿ãŒãã§ãã³å容äœãæ¬ æããããŠã¹ã䜿çšããããããšã䜵çšçæ³ã¯ãã®å¹æã倱ã£ãã 第3ã®å±€ã¯PD-L1ââå€ãã®çãTçŽ°èæ»æãåé¿ããããã«å©çšããå ç«ãã§ãã¯ãã€ã³ãã¿ã³ãã¯è³ªââã«é¢ããããã«ããµã«ã¿ã³ã¯è «ç现èã®PD-L1ãæžå°ãããããããŒããã¹ããŒã ã¯ãããçžä¹å¹æã«å¿ é ã§ã¯ãªãããšã瀺ããââ䜵çšçæ³ã¯PD-L1æ¬ æçްèã§ãåçã«æ©èœããã䜵çšã§èгå¯ãããPD-L1ã®å¢å ã¯ãå®éã«ã¯ã€ã³ã¿ãŒãã§ãã³å¿çã®çµæã§ãããå¹æã®æšé²èŠå ã§ã¯ãªãã BRCAé°æ§è «çãåå¿ éèŠãªæ©æž¡ãççºèŠã¯ããã®çžä¹å¹æãBRCAå€ç°ãä»ã®çžåçµæãæ¬ æã®ãªãè «çã§ãæ©èœããããšã§ãããç ç©¶è ãã¯åµå·£çãå€§è žçãããªãã«ãã¬ãã£ãä¹³çãèè±çã®è€æ°ã®çŽ°èæ ªãšããŠã¹è «çã¢ãã«ã§è©Šéšããããã¹ãŠã®ã±ãŒã¹ã§ããã«ããµã«ã¿ã³ãšãªã©ããªãã®äœµçšã¯ãã©ã¡ããäžæ¹åç¬ãããææã«è «ç墿®ãæå¶ããã ãããã«ããPARPé»å®³å€ã®æçšæ§ãããåºãæ£è éå£ã«æ¡å€§ã§ããå¯èœæ§ããããŸãããšãæ¬ç ç©¶ã®ç¬¬äžèè ã§UT Health San Antonio倧åŠé¢çç©å»ç§åŠç§ã§å士ç ç©¶ãšããŠãã®ç ç©¶ãè¡ã£ãClare E. Murrayæ°ã¯è¿°ã¹ãã Curielæ°äž»å°ã®ããšãããŒããã¹ã»ãããã³ãã¯å»çã»ã³ã¿ãŒã§ã¯æ¢ã«2ä»¶ã®èšåºè©Šéšãé²è¡äžã§ããã第1çžè©ŠéšïŒNCT06168487ïŒã¯ã転移æ§å»å¢æµææ§åç«è ºçã®ç·æ§ã察象ã«ããã«ããµã«ã¿ã³ãšãªã©ããªãããã³ä»ã®æšæºæ²»çè¬ã詊éšããŠãããæåã®åå è ã¯æ²»éšè²¬ä»»å»åž«ãããäŸå€çãªåå¿ããšè¡šçŸããçµæã瀺ããŠããã第2çžè©ŠéšïŒNCT06815497ïŒã¯ããã©ããæµææ§åµå·£çã®å¥³æ§ã察象ã«ããã«ããµã«ã¿ã³ãšååŠçæ³ã®äœµçšã詊éšããŠããã 䞡詊éšãšãåææ®µéã®åæœèšéç²æ€è©Šéšã§ãããéåžžã®æ³šæäºé ãé©çšããããåèšåºç ç©¶ã¯ãã¹ãŠçŽ°èæ ªãšããŠã¹ã¢ãã«ã§å®æœããããã«ããµã«ã¿ã³ã®éARBéšåïŒçžä¹å¹æãæ ãååã®äžéšïŒã®æ£ç¢ºãªååæšçã¯ç¹å®ãããŠããªããç ç©¶è ãã¯ã芳å¯ããã广ã«ã€ããŠãä»ã®ã¡ã«ããºã ãé€å€ããªãã£ãããšè¿°ã¹ãŠããã ããã§ãããã«ããµã«ã¿ã³ã®ãã©ãã°ãªããŒãã·ã³ã°ã«ãããå©ç¹ã¯æããã§ããïŒç±³åœFDAã«æ¿èªããããžã§ããªãã¯ãšããŠå ¥æå¯èœã§ãæ£åžžè¡å§ã®äººã§ãå®å šã§ããã1æ¥1åã®çµå£æäžã§æžããèšåºè©Šéšãåèšåºã®ç¥èŠã確èªããã°ããã®äœµçšçæ³ã¯æ°èŠè¬å€ãããã¯ããã«æ©ãæ£è ã«å±ãå¯èœæ§ãããã é å èš³ åºå ž: Murray, C.E., Ontiveros, C.O., Wentworth, J. et al.ãTelmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production.ãJournal for ImmunoTherapy [âŠ]










